Galenicap BV

Galenicap is a pharmaceutical development company that specializes in 'value-added medicines'—improving existing drug molecules to create clinically differentiated therapies. The company operates as an incubator, identifying academic concepts and existing compounds to advance them through formulation, intellectual property development, and early-stage clinical proof-of-concept. By leveraging a platform that focuses on de-risked biology and known mechanisms, Galenicap aims to accelerate development timelines and address unmet medical needs. The company frequently utilizes a Special Purpose Vehicle (SPV) model to finance and manage specific therapeutic programs, often collaborating with university hospitals, academic institutions, and industry partners.